FDG PET-CT as an important diagnostic tool and prognostic marker in suspected recurrent cervical carcinoma after radiotherapy: comparison with MRI

1Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21669Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A et al Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries CA Cancer J Clin 2021 71 209 49 10.3322/caac.2166934232515Open DOISearch in Google Scholar

2Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018; 143(Suppl 2): S22-36. doi: 10.1002/ijgo.13865Bhatla N Aoki D Sharma DN Sankaranarayanan R Cancer of the cervix uteri Int J Gynaecol Obstet 2018 143Suppl 2 S22 36 10.1002/ijgo.13865929821334669203Open DOISearch in Google Scholar

3Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95(Suppl 1): S43-103. doi: 10.1016/S0020-7292(06)60030-1Quinn MA Benedet JL Odicino F Maisonneuve P Beller U Creasman WT et al Carcinoma of the cervix uteri FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006 95Suppl 1 S43 103 10.1016/S0020-7292(06)60030-129644676Open DOISearch in Google Scholar

4Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF, Rawlings G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer 1993; 3: 193-8. doi: 10.1046/j.1525-1438.1993.03040193.xThomas GM Dembo AJ Myhr T Black B Pringle JF Rawlings G Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery Int J Gynecol Cancer 1993 3 193 8 10.1046/j.1525-1438.1993.03040193.x11578344Open DOISearch in Google Scholar

5Gandy N, Arshad MA, Park WE, Rockall AG, Barwick TD. FDG-PET Imaging in cervical cancer. Semin Nucl Med 2019; 49: 461-70. doi: 10.1053/j.semnu-clmed.2019.06.007.Gandy N Arshad MA Park WE Rockall AG Barwick TD FDG-PET Imaging in cervical cancer Semin Nucl Med 2019 49 461 70 10.1053/j.semnu-clmed.2019.06.007Open DOISearch in Google Scholar

6Patel-Lippmann K, Robbins JB, Barroilhet L, Anderson B, Sadowski EA, Boyum J. MR imaging of cervical cancer. Magn Reson Imaging Clin N Am 2017; 25: 635-49. doi: 10.1016/j.mric.2017.03.007Patel-Lippmann K Robbins JB Barroilhet L Anderson B Sadowski EA Boyum J MR imaging of cervical cancer Magn Reson Imaging Clin N Am 2017 25 635 49 10.1016/j.mric.2017.03.00728668164Open DOISearch in Google Scholar

7Palaniswamy SS, Borde CR, Subramanyam P. 18F-FDG PET/CT in the evaluation of cancer cervix: where do we stand today? Nucl Med Commun 2018; 39: 583-92. doi: 10.1097/MNM.0000000000000851Palaniswamy SS Borde CR Subramanyam P 18F-FDG PET/CT in the evaluation of cancer cervix: where do we stand today? Nucl Med Commun 2018 39 583 92 10.1097/MNM.000000000000085129683929Open DOISearch in Google Scholar

8Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 2007; 7: 164. doi:10.1186/1471-2407-7-164Vinh-Hung V Bourgain C Vlastos G Cserni G De Ridder M Storme G et al Prognostic value of histopathology and trends in cervical cancer: a SEER population study BMC Cancer 2007 7 164 10.1186/1471-2407-7-164199495417718897Open DOISearch in Google Scholar

9Cancer.Net. Cervical Cancer: Statistics. [Internet]. American Society of Clinical Oncology (ASCO); c2005-21. [cited 2021 Aug 17]. Available from: https://www.cancer.net/cancer-types/cervical-cancer/statisticsCancer.Net. Cervical Cancer: Statistics. [Internet]. American Society of Clinical Oncology (ASCO) c2005-21. [cited 2021 Aug 17]. Available from https://www.cancer.net/cancer-types/cervical-cancer/statisticsSearch in Google Scholar

10Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007; 110: 1738-44. doi: 10.1002/cncr.22974Kidd EA Siegel BA Dehdashti F Grigsby PW The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival Cancer 2007 110 1738 44 10.1002/cncr.2297417786947Open DOISearch in Google Scholar

11Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010; 28: 2108-13. doi: 10.1200/JCO.2009.25.4151Kidd EA Siegel BA Dehdashti F Rader JS Mutch DG Powell MA et al Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis J Clin Oncol 2010 28 2108 13 10.1200/JCO.2009.25.415120308664Open DOISearch in Google Scholar

12Yen TC, See LC, Lai CH, Tsai CS, Chao A, Hsueh S, et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging 2008; 35: 493-501. doi: 10.1007/s00259-007-0612-1Yen TC See LC Lai CH Tsai CS Chao A Hsueh S et al Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer Eur J Nucl Med Mol Imaging 2008 35 493 501 10.1007/s00259-007-0612-117955238Open DOISearch in Google Scholar

13Han S, Kim H, Kim YJ, Suh CH, Woo S. Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in uterine cervical cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 2018; 211: 1112-21. doi: 10.2214/AJR.18.19734Han S Kim H Kim YJ Suh CH Woo S Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in uterine cervical cancer: a systematic review and meta-analysis AJR Am J Roentgenol 2018 211 1112 21 10.2214/AJR.18.1973430207790Open DOISearch in Google Scholar

14Miccò M, Vargas HA, Burger IA, Kollmeier MA, Goldman DA, Park KJ, et al. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. Eur J Radiol 2014; 83: 1169-76. doi: 10.1016/j.ejrad.2014.03.024Miccò M Vargas HA Burger IA Kollmeier MA Goldman DA Park KJ et al Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer Eur J Radiol 2014 83 1169 76 10.1016/j.ejrad.2014.03.02424767630Open DOISearch in Google Scholar

15Ho JC, Allen PK, Bhosale PR, Rauch GM, Fuller CD, Mohamed AS, et al. Diffusion-weighted magnetic resonance imaging as a predictor of outcome in cervical cancer after chemoradiation. Int J Radiat Oncol Biol Phys 2017; 97: 546-53. doi: 10.1016/j.ijrobp.2016.11.015Ho JC Allen PK Bhosale PR Rauch GM Fuller CD Mohamed AS et al Diffusion-weighted magnetic resonance imaging as a predictor of outcome in cervical cancer after chemoradiation Int J Radiat Oncol Biol Phys 2017 97 546 53 10.1016/j.ijrobp.2016.11.015611261228011045Open DOISearch in Google Scholar

16Tavassoéli FA, Devilee P. IARC WHO classification of tumours, pathology and genetics tumours of the breast and female genital organs. Vol 4. 3rd edition. Lyon: IARC publications; 2003.Tavassoéli FA Devilee P IARC WHO classification of tumours, pathology and genetics tumours of the breast and female genital organs. Vol 4. 3rd edition Lyon IARC publications; 2003Search in Google Scholar

17Kurman RJ, Hedrick-Ellenson L, Ronnett BM. Blaustein’s pathology of the female genital tract. 6th edition. New York: Springer; 2011.Kurman RJ Hedrick-Ellenson L Ronnett BM Blaustein’s pathology of the female genital tract. 6th edition New York Springer 201110.1007/978-1-4419-0489-8Search in Google Scholar

18Meads C, Davenport C, Małysiak S, Kowalska M, Zapalska A, Guest P, et al. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. BJOG 2014; 121: 398-407. doi: 10.1111/1471-0528.12460Meads C Davenport C Małysiak S Kowalska M Zapalska A Guest P et al Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation BJOG 2014 121 398 407 10.1111/1471-0528.1246024299112Open DOISearch in Google Scholar

19Chu Y, Zheng A, Wang F, Lin W, Yang X, Han L, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun 2014; 35: 144-50. doi: 10.1097/MNM.0000000000000026Chu Y Zheng A Wang F Lin W Yang X Han L et al Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis Nucl Med Commun 2014 35 144 50 10.1097/MNM.000000000000002624177043Open DOISearch in Google Scholar

20Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2010; 37: 1270-8. doi: 10.1007/s00259-010-1417-1Pallardy A Bodet-Milin C Oudoux A Campion L Bourbouloux E Sagan C et al Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma Eur J Nucl Med Mol Imaging 2010 37 1270 8 10.1007/s00259-010-1417-120306032Open DOISearch in Google Scholar

21Bjurberg M, Brun E. Clinical impact of 2-deoxy-2-[18F] fluoro-D-glucose (FDG)-positron emission tomography (PET) on treatment choice in recurrent cancer of the cervix uteri. Int J Gynecol Cancer 2013; 23: 1642-6. doi: 10.1097/IGC.0b013e3182a50537Bjurberg M Brun E Clinical impact of 2-deoxy-2-[18F] fluoro-D-glucose (FDG)-positron emission tomography (PET) on treatment choice in recurrent cancer of the cervix uteri Int J Gynecol Cancer 2013 23 1642 6 10.1097/IGC.0b013e3182a5053724177254Open DOISearch in Google Scholar

22Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cervical carcinoma with dual-phase [18F] fluoro-2-deoxy-D-glucose positron emission tomography. Cancer 2004; 100: 544-52. doi: 10.1002/cncr.11928Lai CH Huang KG See LC Yen TC Tsai CS Chang TC et al Restaging of recurrent cervical carcinoma with dual-phase [18F] fluoro-2-deoxy-D-glucose positron emission tomography Cancer 2004 100 544 52 10.1002/cncr.1192814745871Open DOISearch in Google Scholar

23Yen TC, Lai CH, Ma SY, Huang KG, Huang HJ, Hong JH, et al. Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1399-407. doi: 10.1007/s00259-006-0090-xYen TC Lai CH Ma SY Huang KG Huang HJ Hong JH et al Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer Eur J Nucl Med Mol Imaging 2006 33 1399 407 10.1007/s00259-006-0090-x16847653Open DOISearch in Google Scholar

24Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004; 22: 2167-71. doi: 10.1200/JCO.2004.09.035Grigsby PW Siegel BA Dehdashti F Rader J Zoberi I Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome J Clin Oncol 2004 22 2167 71 10.1200/JCO.2004.09.03515169804Open DOISearch in Google Scholar

25Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007; 298: 2289-95. doi: 10.1001/jama.298.19.2289Schwarz JK Siegel BA Dehdashti F Grigsby PW Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma JAMA 2007 298 2289 95 10.1001/jama.298.19.228918029833Open DOISearch in Google Scholar

26Kim YJ, Han S, Kim YS, Nam JH. Prognostic value of post-treatment 18F-fluorodeoxyglucose positron emission tomography in uterine cervical cancer patients treated with radiotherapy: a systematic review and meta-analysis. J Gynecol Oncol 2019; 30: e66. doi: 10.3802/jgo.2019.30.e66.Kim YJ Han S Kim YS Nam JH Prognostic value of post-treatment 18F-fluorodeoxyglucose positron emission tomography in uterine cervical cancer patients treated with radiotherapy: a systematic review and meta-analysis J Gynecol Oncol 2019 30 e66 10.3802/jgo.2019.30.e66665859731328452Open DOISearch in Google Scholar

27Onal C, Guler OC, Reyhan M, Yapar AF. Long-term outcomes of cervical cancer patients with complete metabolic response after definitive chemoradiotherapy. J Gynecol Oncol 2021; 32: e74. doi: 10.1016/j.clon.2021.03.022Onal C Guler OC Reyhan M Yapar AF Long-term outcomes of cervical cancer patients with complete metabolic response after definitive chemoradiotherapy J Gynecol Oncol 2021 32 e74 10.1016/j.clon.2021.03.02233906779Open DOISearch in Google Scholar

28Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Predictive role of post-treatment [18F] FDG PET/CT in patients with uterine cervical cancer. Eur J Radiol 2012; 81: e817-e822. doi: 10.1016/j.ejrad.2012.02.015Chung HH Kim JW Kang KW Park NH Song YS Chung JK et al Predictive role of post-treatment [18F] FDG PET/CT in patients with uterine cervical cancer Eur J Radiol 2012 81 e817 e822 10.1016/j.ejrad.2012.02.01522595504Open DOISearch in Google Scholar